Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Liver Metastases
Stage IVA Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IVA Colon Cancer

Interventions: Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Biological: bevacizumab
Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Other: laboratory biomarker analysis
Other: pharmacological study
Drug: irinotecan hydrochloride

First Posted Date: 2011-03-22

Last Posted Date: 2016-07-19

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 1

Registration Number: NCT01320683

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer

Phase 2

Terminated

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Esophageal Adenocarcinoma
Stage IIA Esophageal Cancer
Stage IIB Esophageal Cancer

Interventions: Drug: Fluorouracil
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Biological: Panitumumab
Other: Pharmacological Study
Radiation: Radiation Therapy
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2011-03-03

Last Posted Date: 2023-10-26

Lead Sponsor: University of Nebraska

Target Recruit Count: 11

Registration Number: NCT01307956

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer

Phase 3

Conditions: CRC

Interventions: Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2011-03-03

Last Posted Date: 2017-08-09

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 2000

Registration Number: NCT01308086

Locations: 🇬🇷
University Hospital of Crete, Dep of Medical Oncology, Heraklion, Greece

Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma

Phase 1

Withdrawn

Conditions: Stage II Rectal Cancer
Stage III Rectal Cancer

Interventions: Drug: Capecitabine
Drug: 5-FU
Drug: Leucovorin
Drug: Oxaliplatin
Radiation: radiation
Procedure: total mesorectal excision

First Posted Date: 2011-02-24

Last Posted Date: 2020-08-20

Lead Sponsor: University of Texas Southwestern Medical Center

Registration Number: NCT01302613

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Not Applicable

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Drug: irinotecan hydrochloride
Drug: capecitabine
Genetic: mutation analysis
Biological: bevacizumab
Biological: cetuximab
Genetic: gene expression analysis
Other: laboratory biomarker analysis
Other: immunohistochemistry staining method
Genetic: nucleic acid sequencing
Genetic: protein expression analysis
Genetic: polymerase chain reaction
Genetic: DNA analysis

First Posted Date: 2011-01-21

Last Posted Date: 2021-03-15

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT01280643

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Phase 3

Terminated

Conditions: Cognitive/Functional Effects
Colorectal Cancer
Neurotoxicity

Interventions: Biological: bevacizumab
Drug: capecitabine
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2011-01-19

Last Posted Date: 2017-12-08

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 32

Registration Number: NCT01279681

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Withdrawn

Conditions: Recurrent Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Stage IVA Rectal Cancer
Stage IVA Colon Cancer

Interventions: Drug: FOLFOX regimen
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Biological: bevacizumab
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil

First Posted Date: 2011-01-05

Last Posted Date: 2017-04-04

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT01270438

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Leucovorin
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Radiation: radiation therapy

First Posted Date: 2010-12-20

Last Posted Date: 2016-09-21

Lead Sponsor: Cardiff University

Target Recruit Count: 60

Registration Number: NCT01263171

Locations: 🇬🇧
Walsgrave Hospital, Coventry, England, United Kingdom
🇬🇧
Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom
🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

and more 4 locations

A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer

Phase 2

Completed

Conditions: Adenocarcinoma
Esophageal Cancer

Interventions: Drug: Nimotuzumab
Drug: Cisplatin
Drug: Fluorouracil
Radiation: Radiotherapy

First Posted Date: 2010-11-29

Last Posted Date: 2014-01-06

Lead Sponsor: Eurofarma Laboratorios S.A.

Target Recruit Count: 104

Registration Number: NCT01249352

Locations: 🇧🇷
Hospital Nossa Senhora da Conceição, Porto Alegre, RS, Brazil
🇧🇷
Santa Casa de Misericórdia de BH, Belo Horizonte, MG, Brazil
🇧🇷
Hospital Geral de Bonsucesso, Rio de Janeiro, RJ, Brazil

and more 16 locations

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Stomach Cancer

Interventions: Biological: Ramucirumab
Drug: Placebo
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-Fluorouracil

First Posted Date: 2010-11-24

Last Posted Date: 2014-10-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 168

Registration Number: NCT01246960

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marshfield, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy